Companies: 10,795·Total market cap: $144.5T
Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics, Inc.

ARQTNASDAQHealthcare● Active
$21.54
+$0.31(+1.46%)
Market Cap$2.7B
P/E Ratio
52W High$31.77
52W Low$12.72
Overview

Arcutis Biotherapeutics, Inc. (ARQT) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001787306 · ARQT · NASDAQ · as of Jun 9, 2026

Filing snapshot

799
Total Filings
8-K
Latest Form
2026-06-09
Most Recent
2020
Filing Since

Source: SEC EDGAR (data.sec.gov) · CIK 0001787306 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2026-02-25
Fiscal Year End
Feb 25, 2026
Accession No.
0001787306-26-000018
Primary Document
arqt-20251231.htm
Source: data.sec.gov · CIK 0001787306 · Accession 0001787306-26-000018

Latest Key Filings

10-QQuarterly Report
10-Q
2026-05-06
8-KCurrent Report
8-K
2026-06-09Material Event
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

SEC Filing History

Hide Form 4 / 144
8-KCurrent Report
8-K
2026-06-09
View
SCHEDULE 13GSCHEDULE 13G
SCHEDULE 13G
2026-05-12
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-05-08
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-05-06
View
10-QQuarterly Report
10-Q
2026-05-06
View
8-KCurrent Report
8-K
2026-05-06
View
S-8Employee Stock Plan Registration
S-8
2026-04-21
View
ARSARS
ARS
2026-04-21
View
DEFA14AProxy Statement (Additional)
DEFA14A
2026-04-21
View
DEF 14AProxy Statement
DEF 14A
2026-04-21
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-03-26
View
S-8Employee Stock Plan Registration
S-8
2026-02-25
View
S-3ASRS-3ASR
S-3ASR
2026-02-25
View
10-KAnnual Report
10-K
2026-02-25
View
8-KCurrent Report
8-K
2026-02-25
View
Showing 1–15 of 279 filingsForm 4 / 144 hidden· 799 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001787306  |  Exchange: NASDAQ · Healthcare

Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) has submitted 799 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2020. As a Healthcare sector company with CIK 0001787306, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Arcutis Biotherapeutics, Inc.'s most comprehensive regulatory disclosure. The most recent Arcutis Biotherapeutics, Inc. 10-K was filed on 2026-02-25 for fiscal year ending 2026. Historical ARQT 10-K annual reports are available from 2019 through 2026.

Investors researching Arcutis Biotherapeutics, Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-09

Frequently Asked Questions

ARQT SEC Filings · 8 questions

Arcutis Biotherapeutics, Inc. (ARQT) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 799 filings and access original documents at no cost. Arcutis Biotherapeutics, Inc.'s CIK is 0001787306.

ARQT SEC filingsArcutis Biotherapeutics, Inc. SEC documentsfind ARQT 10-K